Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eluxadoline

Next Previous
Drug Profile

Eluxadoline

Alternative Names: JNJ-27018966; Mu Delta; TRUBERZI; VIBERZI

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Allergan
  • Class Amides; Benzoic acids; Imidazoles; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Opioid delta receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Irritable bowel syndrome

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 Nov 2017 Allergan initiates enrolment in a phase II trial for Irritable bowel syndrome in USA, Bulgaria, Canada and Poland (NCT03339128)
  • 09 Nov 2017 Allergan plans a phase II trial for Irritable Bowel Syndrome (In Children) in USA, Bulgaria, Canada, Poland (NCT03339128)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top